Blockbuster sales of its flagship GLP-1 treatments have propelled Eli Lilly And Co.‘s (NYSE:LLY) first-quarter earnings, prompting a prominent Wall Street analyst to defend the stock’s valuation and highlight the disruptive potential of its new oral weight-loss drug.
Fueling The ‘Love Affair’
Eli Lilly’s revenue skyrocketed 56% year-over-year to $19.8 billion during its first-quarter 2026, driven primarily by the astronomical volume demand for its metabolic and weight-management medications.
Following the earnings release, Gary Black, Managing Partner of The Future Fund, noted on X that Eli Lilly continues to heavily capitalize on consumers’ ongoing “love affair” with GLP-1 drugs.
The financial results reflect this devotion: worldwide revenue for the diabetes drug Mounjaro surged over 120% year-over-year to $8.7 billion, while the obesity treatment Zepbound brought in nearly $4.2 billion, an 80% year-over-year increase.
data-variant=”card”
data-news-mode=”manual”
>
Read Also:
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand
This post was originally published here
